Chlorella Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Chlorella Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), represents a spectrum of metabolic disorders characterized by excessive fat accumulation in the liver, affecting more than 5% of hepatocytes. [Jafari Ali (2026); evidence level 1]
• A significant proportion of NAFLD patients exhibit features of metabolic syndrome, including insulin resistance, dyslipidemia, hypertension, and obesity, all of which substantially increase the risk of cardiovascular disease (CVD). [Jafari Ali (2026); evidence level 1]
• Chlorella 5 7 8 9 10 Emerging evidence suggests that supplementation withand spirulina may be associated with improvements in metabolic parameters such as insulin sensitivity, lipid profiles, and hepatic steatosis markers while simultaneously reducing systemic inflammatory burden and oxidative stress. [Rzeski Wojciech (2026); evidence level 3]
• We also discuss clinical evidence, safety considerations, and translational perspectives, highlighting current knowledge gaps and future research directions necessary for the rational development of microalgae-based interventions in preventive and integrative medicine. [Rzeski Wojciech (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For chlorella blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Jafari Ali (2026). The beneficial effects of Chlorella vulgaris supplementation on health-related indices in patients with non-alcoholic fatty liver disease: a GRADE-assessed systematic review and meta-analysis. DOI: 10.1186/s12872-025-05433-w. PMCID: PMC12977676. PMID: 41652544. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12977676/
• Rzeski Wojciech (2026). Chlorella and Arthrospira (Spirulina) as Multi-Pathway Biological Response Modulators: Molecular Mechanisms, Signaling Pathways and Clinical Evidence. DOI: 10.3390/molecules31101595. PMCID: PMC13209791. PMID: 42197149. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209791/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.